Physician profile
Hans Yu
NPI 1811089303
$5,315.80
in general payments reported to CMS, 2019-2025
33 companies · $992 in 2025
The $992 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $637 · 2021: $712 · 2022: $494 · 2023: $870 · 2024: $801 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,649 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,648.94 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $777.79 | 2019-2025 | Vemlidy |
| Pfizer INC. | $498.23 | 2021-2025 | |
| Novo Nordisk INC | $476.17 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $461.56 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Amgen INC. | $458.50 | 2019-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $407.68 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $331.37 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $313.36 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $299.46 | 2020-2025 | Linzess, Ubrelvy, Qulipta |
| Lilly USA, LLC | $245.04 | 2019-2025 | Mounjaro, Kisunla |
| Novartis Pharmaceuticals Corporation | $114.00 | 2020-2025 | |
| Astellas Pharma US INC | $107.15 | 2020-2022 | |
| Amarin Pharma, INC. | $93.78 | 2020-2021 | |
| Evofem Biosciences, INC. | $82.84 | 2024-2025 | Solosec, Phexx, Phexxi |
| Glaxosmithkline, LLC. | $73.76 | 2024-2025 | Arexvy, Shingrix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $68.04 | 2019-2023 | |
| Esperion Therapeutics, INC. | $52.78 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $49.83 | 2019-2023 | Eliquis |
| Seqirus USA INC | $43.14 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Allergan, INC. | $37.53 | 2019 | |
| Agios Pharmaceuticals, INC. | $35.74 | 2025 | Pyrukynd |
| Ironwood Pharmaceuticals, INC | $34.83 | 2020 | |
| Novavax INC | $33.05 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Radius Health, INC. | $29.92 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.26 | 2019 | |
| Exact Sciences Corporation | $24.91 | 2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $23.97 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $22.14 | 2025 | Rexulti |
| Vifor Pharma, INC. | $20.17 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.55 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.34 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.91 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hans Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.